Elizabeth Olson Hexner, M.D., M.S.T.R.
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania - Rhoads 7 Liquid Tumor Service
Department: Medicine
Contact information
Perelman Center for Advanced Medicine
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
2 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215.614.1847
Fax: (215) 615-5888
Fax: (215) 615-5888
Education:
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
A.B. (French/Comparative Area Studies)
Duke University, 1992.
(Premedical Studies)
Harvard University Extension School, 1994.
M.D. (Medicine)
Columbia College of Physicians and Surgeons, 1999.
M.S.T.R. (Translational Research)
University of Pennsylvania, 2009.
Post-Graduate Training
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Intern, Department of Medicine, Columbia Presbyterian Hospital, 1999-2000.
Resident, Department of Medicine, Columbia Presbyterian Hospital, 2000-2002.
Fellow, Hematology/Oncology, University of Pennsylvania, 2002-2005.
Certifications
American Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Hematology), 2005.
American Board of Internal Medicine (Medical Oncology), 2005.
Permanent linkAmerican Board of Internal Medicine (Internal Medicine), 2002.
American Board of Internal Medicine (Hematology), 2005.
American Board of Internal Medicine (Medical Oncology), 2005.
Description of Research Expertise
Myeloproliferative DisordersUmbilical Cord Blood Transplantation
Description of Clinical Expertise
Myeloproliferative NeoplasmsMyelodysplastic Syndromes
Acute leukemia
Selected Publications
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Raza, A., Vaddi, K., Sun, W., Peng, W., Sandor, V., Kantarjian, H.: Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study. Haematologica 2015.Hexner, E. O., Mascarenhas, J., Prchal, J., Roboz, G. J., Baer, M. R., Ritchie, E. K., Leibowitz, D., Demakos, E. P., Miller, C., Siuty, J., Kleczko, J., Price, L., Jeschke, G., Weinberg, R., Basu, T. T., Pahl, H. L., Orazi, A., Najfeld, V., Marchioli, R., Goldberg, J. D., Silverman, L. R., Hoffman, R.: Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leuk Lymphoma Page: 1-26, 2015.
Bolanos-Meade, J., Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., Ho, V. T.: Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute graft-versus-host disease: BMT CTN 0802. Blood 2014.
Hexner, E: Essential Thrombocythemia. Rare Disease Database, National Organization for Rare Diseases (NORD) 2014 Notes: https://www.rarediseases.org/rare-disease-information/rare-diseases/byID/577/viewFullReport.
Babushok, D., Hexner, E.: Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? Curr Opin Hematol 21(2): 114-22, 2014.
Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., Hexner, E., Zhang, Y.: Ezh2 Regulates Transcriptional and Posttranslational Expression of T-bet and Promotes Th1 Cell Responses Mediating Aplastic Anemia in Mice. J Immunol 2014.
Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, Clementi R, Bensen-Kennedy D, and Moliterno A.: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with the JAK2-V617F mutation. Br J Haematol 164: 83–93, 2014.
Reshef, R., Hexner, E. O., Loren, A. W., Frey, N. V., Stadtmauer, E. A., Luger, S. M., Mangan, J. K., Gill, S. I., Vassilev, P., Lafferty, K. A., Smith, J., Van Deerlin, V. M., Mick, R., Porter, D. L.: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2014.
Babushok, D. V., Cardamone, D., Rulander, N., Master, S. R., Hexner, E. O.: A Common, Under-Recognized Cause of Elevated Serum Erythropoietin. Am J Med 2014.
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., Dipersio, J. F., Catalano, J. V., Deininger, M. W., Miller, C. B., Silver, R. T., Talpaz, M., Winton, E. F., Harvey, J. H., Arcasoy, M. O., Hexner, E. O., Lyons, R. M., Paquette, R., Raza, A., Vaddi, K., Erickson-Viitanen, S., Sun, W., Sandor, V., Kantarjian, H. M.: Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013.
